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Abstract

In later stages of retinal degenerative diseases such as age-related macular degeneration (AMD)
and retinitis pigmentosa stem cell therapy can be the only viable treatment option due to the loss
of photoreceptor and RPE cells. Differentiation of embryonic stem cells (ESCs) towards the
desired lineage explicitly requires a microenvironment that mimics the natural tissue that it is
intended to regenerate. Developing a planar 3D retinal graft derived from ESCs can be transplanted
to treat various retinal degeneration diseases. Our aim was to explore the differentiation and growth
of ESCs on a gelatinous scaffold in order to transplant into a retinitis pigmentosa mouse model
(RD10). Our aim was to evaluate the transplanted graft for host inflammatory response, stem cell
integration, cell survival, and tumorigenesis. The transplanted graft was also compared to injection
of a homogenous photoreceptor cell population into the subretinal space of the RD10 mouse
model. A biocompatible gelatinous scaffold was developed in order to support the differentiation
of a multilayered retinal structure. ESCs were seeded onto the scaffold for proliferation and
differentiation in the vicinity of retinal pigment epithelium cells. Cultures were analyzed for
differentiation by qRT-PCR and immunofluorescence confocal microscopy. The graft was
transplanted into the subretinal space to examine biocompatibility and retinal progenitor cell
integration into the native mouse retina. ESCs migrated through the 60µm thickness of the scaffold
and differentiated into the retinal progenitor cells as evidenced by qRT-PCR and
immunohistochesmistry. In-vivo testing analyzed on 1st, 3rd and 6th week showed scaffold
degradation by the 6th week. The gelatinous scaffold supported the differentiation of ESCs to RPCs
and minimal inflammatory response was seen post transplantation.
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Introduction
Retinal Degeneration and future Intervention Methods
Patients with retinal degenerative diseases have many pathways which are negatively affected in
photoreceptor cells. Pathways such as phototransduction, lipid metabolism, RNA splicing, inner
and outer segment formation of photoreceptor cells, vesicle trafficking and protein folding can be
malfunctioning (1). The retinal pigment epithelium (RPE) underlying the photoreceptor layer,
responsible for nourishing the retina, can have mutations in phagocytosis, light sensitive rhodopsin
regeneration, and ion trafficking causing photoreceptor dysfunction and ultimately death of these
cells (2,3).

Figure 1- Strategies used to treat retinal degeneration at different time points. Gene therapy is
used at earlier stages when the photoreceptors are intact. Pharmacotherapy and neuroprotective
strategies are suitable in ongoing photoreceptor cell degeneration. Stem cell therapy,
optogenetic therapy, and retinal prostheses are needed to restore vision during the later stages
of retinal degeneration. (Figure adapted from 3a)
Pharmacotherapy or neuroprotective agents can be used in early stages of the disease when the
photoreceptors are still viable. Gene therapy can be used when there is a single genetic mutation
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that can be corrected using the CRISPR/Cas9 system or AAV vector transfection containing the
corrected gene insert (4,5). However, in a heterogeneous retinal degenerative disease when there
is not a single genetic mutation and in later stages of the disease when the photoreceptor cells are
not viable, retinal stem cell replacement can be the only solution to vision restoration or
preservation.
Retinal degenerative diseases such as age-related macular degeneration (AMD), Stargardt disease,
and retinitis pigmentosa, are phenotypically diverse but can be treated with stem cell therapy (6,7).
In the population above the age of 55, AMD is the leading cause of blindness worldwide. AMD
affects 1.75 million people in the USA alone and will affect nearly 196 million people worldwide
by 2020 (8).
Retinitis pigmentosa (RP) encompasses a heterogenous group of progressive retinal degenerative
disorders with a worldwide prevalence of 1 in 3500–5000 individuals (9). Patients with RP
typically present in later stages of the disease given that their central vision remains intact for a
long time. These and many other currently untreatable retinal conditions are the subject of many
clinical trials using embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) to
treat these underlying conditions (10,11)
During retinogenesis, ESCs undergo a stepwise developmental process through primitive eye field
(EF) and retinal progenitor cell (RPC) stages and then commit to neuronal and photoreceptor
subtypes (12).
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Retinitis Pigmentosa and retinal stem cell Transplantation

a

b

Figure 2- Panel A: fundus photograph of a patient suffering from retinitis pigmentosa. In
the areas with increased dark pigmentation photoreceptor death has occurred as the pigment
in the underlying RPE is easily evident. Panel B is demonstrating a healthy retina for
comparison.

Retinitis pigmentosa (RP) is an inherited disease which claims a person’s vision over decades.
There are still many unknown genetic mutations that can cause RP. It is difficult to develop a
single specific gene therapy as patients afflicted with RP have an extensive disease causing genetic
heterogeneity (13). Loss of functional proteins leads to disruption of normal photoreceptor cell
structure causing cell death and irreversible blindness. As one example, Lamba et al. (14),
transplanted retinal progenitor cell (RPC) suspensions into normal mice and mice with
photoreceptor genetic defect. This experiment showed that the RPC could migrate and integrate
into the various layers of the retina, but only if they were injected before the retinal degeneration
began. A careful reading of the report reveals that transplanted RPC slowed the progression of the
disease, but could not reverse the degeneration that had already occurred (13). The RPC graft
suspensions fail when they are introduced into a diseased environment. By engineering the RPCs
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into a flat tissue in which cell-cell interactions are already established, or by developing a
homogenous photoreceptor cell population, the graft might survive and integrate with the remnants
of the host tissue to restore lost vision.

Planar retinal graft development

a

b

Figure 3- The illustration depicts the layered retinal anatomy and injection of stem cells
into the subretinal space of the mouse eye using a trans-scleral approach given the lens is
bigger in mice compared to human eyes. Panel a is adapted from 4a. Panel b courtesy of
L. Rizzolo, Yale Univ.
The problem confronting the field is that the more mature assemblies of differentiated RPC cannot
be transplanted for two reasons: The assemblies of retinal-like cells do not survive dissociation to
single cells and injection into the subretinal space. The geometry of the cell assemblies is not
amenable to transplantation. Depending on the protocol the cells form rosettes on a culture dish
or neurospheres in suspension culture. The rosettes and neurospheres are of small diameter and
would have to be converted to flat sheets in order to interact with the host retina and RPE.
Accordingly, the only successful transplantation experiments involve suspensions of immature
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cells in the earliest stages of retinal degeneration. Later investigators achieved some success in late
stage disease using mouse models of retinal degeneration. Rod precursors were purified and the
suspension was injected into the subretinal space after the photoreceptor layer degenerated.
Success depended on the disease model that was used (15,16). Several labs have cultured RPC in
sheets, but the scaffolds used would block interactions with either the host retina or the RPE
(17,18). With designing a biocompatible scaffold that would foster differentiation of H9
embryonic stem cells (ESCs) it is possible to develop planar retinal structures.
Electrospun fibers of ε-polycaprolactone was tested in the Rizzolo lab in prior years. It did foster
ESC differentiation into RPCs. However, it did not allow for full thickness migration (120 µm) of
the cells through the scaffold. This prompted the Rizzolo lab to develop a porous scaffold made
with hyaluronic acid, chondroitin sulfate and gelatin which closely resembles the retinal basement
membrane composition. The gelatinous scaffold was used to differentiate the RPCs in a planar
structure above the retinal pigment epithelium (RPE) layer. The differentiation of ESCs in the
vicinity of RPE mimics the in vivo environment where photoreceptors are naturally developing.
This contact with the RPE can help guide the differentiation of ESCs into photoreceptors in vitro.
There have been many established tissue culture methods that are used to differentiate RPCs into
different retinal cells in vitro. A converging body of data has showed the ability of human
embryonic stem cells (hESC) and induced pluripotent cells (hiPSC) to differentiate into neural
retinal lineages and finally become photoreceptors and interneurons (19). However, to develop
functional photoreceptor outer segments the RPE is required. It is unknown if co-culture with RPE
would induce synapse formation between the photoreceptors and interneurons to create a lightsensitive tissue. I will be using the RPE/RPC coculture method developed by the Rizzolo lab for
developing the retinal graft.
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Ongoing retinal stem cell transplantation clinical trials
ESC derived photoreceptor transplantation trials are still being completed. However, ESC derived
RPE stem cell transplantation has been done. A landmark study of ESC transplantation done by
Schwartz et al. showed that 5x104 ESC-derived RPE cells can successfully be transplanted into
the eye of patients with age related macular degeneration (AMD) and Stargardt’s macular
dystrophy. Four years post transplantation, these Phase 1/2 clinical trials did not show signs of
rejection, ectopic tissue or tumor formation, or hyperproliferation. (10). The ESC-derived RPE
transplantation was done in 18 patients which confirmed long- term safety and graft survival.
Patients tolerated the graft well and the adverse effects were mainly limited to the surgical
procedure and oral immunosuppressive regimen. Even though the eye is considered to be an
immune privileged organ the patients were on an oral immunosuppressive regimen given the cells
were derived from ESC (20). At the end of the trial, there was minimal improvement in bestcorrected visual acuity and quality-of-life measures. More tests such as microperimetry, auto
fluorescence imaging, optical coherence tomography scanning, and multifocal electroretingram
can be done to establish visual function (21). In order to reduce the need for oral
immunosuppressive therapy, iPSC derived RPE can be used if the cells are obtained from the
patient.
Preliminary mouse studies have grafted human iPSC-derived RPE cells into the subretinal space
of mouse eyes. This study found that human iPSC-derived RPE cells restored some retinal function
assessed by electroretinography in a mouse possessing the mutation in a gene known to be
responsible for certain types of retinitis pigmentosa (RP) (22).
PDE6b is a protein that plays a key role in cGMP hydrolysis and photoreceptor hyperpolarization.
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This protein is essential in converting all-trans retinol to 11-cis retinal during photoreceptor
phototransduction and visual pigment regeneration (23).

Figure 4- This panel demonstrates the RD10 mouse retinal histology over time. The outer
nuclear layer (ONL) thinning, which corresponds to photoreceptor degeneration, is
significant by day 30. Arrows are depicting actively dying photoreceptors. Figure adapted
from Gargini C et. al Organization in the retinal degeneration 10 (rd10) Mutant Mouse
(24).
To test retinitis pigmentosa (RP) reversal in vivo, I transplanted our engineered retina into RD10
mice, which has a PDE6b gene knockout. PDE6b KO causes degeneration of rod and cone
photoreceptors and is also a gene that is linked to RP in humans and some cases of Leber congenital
amaurosis (25). Notably, the RD10 mouse’s phenotype causes the photoreceptor layer to
degenerate from full thickness starting at 16 days until photoreceptors are nearly absent after 35
days after in the central retina.
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Statement of Purpose
Aim 1. Develop a planar retinal graft on a gelatinous scaffold for in vivo transplantation of a
homogenous RPC population or purified rod precursors for subretinal injection.
I hypothesize that development of a multilayered planar retinal graft will enhance the
integration of RPCs into the injured photoreceptor layer and further differentiation into the
photoreceptor lineage in vivo. Moreover, I want to compare the transplantation of the RPC/GCH
graft to the injection of a homogenous photoreceptor cell suspension in the subretinal space.
Aim 2. Evaluate the side effects of RPC graft/scaffold transplantation such as tumergenicity,
uveitis, retinal edema, inflammatory response and retinal scaring.
I hypothesize that since the scaffold is mostly made of gelatin, hyaluronic acid, and chondroitin
sulfate and roughly resembles the matrix of the retina that the inflammatory response will be
minimal and the scaffold can be degraded in vivo. Also the since the scaffold is implanted in the
subretinal space, which is immune privileged, inflammatory response is minimum.
Aim 3. Transplantation of in-vitro differentiated RPC into a retinitis pigmentosa mouse models at
the intermediate and late stages of disease.
I hypothesize that RPCs can migrate towards the layer of injury and will integrate in the
photoreceptor layer in the retinitis pigmentosa mouse model given the photoreceptor layer has
undergone 90% degeneration by P30.
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Materials and Methods
C57/BL6 mice and RD10 mice were used at P30. All experiments were done in accordance to
ARVO statement for the use of animal in ophthalmic and vision research. Gelatin powder was
purchased from J.T.Baker, New Jersey (USA). Chondroitin sulfate, 90+% and hyaluronic acid was
obtained from Alfa Aesar, MA (USA). Ammonium persulfate by fisher scientifics, New Jersey
(USA). N,N,N',N'-Tetramethylethylenediamine, Tri-Buffer-saline with 1% tween 20, Phosphate
buffer saline (PBS) 1X , pH 7.4 containing 1.4M NaCl, 0.1M phosphate (pH 7.4) and 0.03M KCl
were all purchased from American BIO, MA (USA). Glutaraldehyde, 50% Ameresco, Ohio
(USA). Milli-Q-grade water was used in all experiments except for gene expression in which
nuclease free-water from Bio-rad. i-Script cDNA synthesis kit, iTaqtm Universal SYBRGreen
Supermix and PCR plates were purchased from Bio-rad, Hercules (USA). All the solvents used
here without any further purification were purchased from Sigma-Aldrich.

Preparation of 3D scaffold
Different combination of polymers was used to fabricate the gelatin-chondroitin sulfate-hyaluronic
acid (GCH) scaffold. 250mg of gelatin, 125mg of chondroitin sulfate and 250mg of hyaluronic
acid were dissolved in water. 50 µl of glutaraldehyde cross-linker with reaction initiator
ammonium-persulphate and redox catalyst N,N,N′,N′-tetramethylethylenediamine (TEMED)
catalyst, were added to the dissolved solution. Polymer solution was frozen at -20 °C for 18 hrs
and vacuum dried using lyophilizer to produce a solid 3D scaffold. Scaffolds which were
mechanically stable enough were frozen in OCT and sectioned using a cryotome to a 60µm
thickness.
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Human Embryonic stem cells (H9) culture maintenance and differentiation
Undifferentiated H9 human embryonic stem cells were obtained from the Yale stem cell center.
Cells were cultured on 1% matrigel coated plates and maintained in mTeSR-1 media. Media was
changed every 2 days and colonies were regularly scraped under a sterile microscope to remove
spontaneously differentiating cells. For passaging, colonies were lifted by incubating with 1U/ml
dispase for 30 min at 37˚c, triturated and washed with DMEM/F-12 nutrient media and plated onto
newly 1% matrigel-coated dishes.
For the RPC differentiation process, H9 cells were treated with blebbestatin following the dispase
step in order to make embryoid bodies (EBs). EBs were cultured in mTeSR-1 at D0. Neural
induction medium (NIM) containing B27 was added the next day (D1) in a ratio of 1: 3 with
mTeSR-1. On D2 the concentration of NIM increased to 1:1 with mTeSR-1 and on D3 and
onwards EBs were cultured in 100% NIM. On D7 the floating EBs were seeded on matrigel coated
6 well plates and continued to be cultured in NIM until D20. The retinal progenitor cells (RPC)
were selected and manually dissected out from the plates for further experimentation.

EBs on GCH scaffold seeding for retinal cup differentiation
EBs formed using H9 were seeded onto GCH scaffold on D20. Scaffolds were sterilized overnight
with 70% ethanol, washed three times with PBS, then treated with pen-strep for 30 mins and
soaked in NIM overnight. 6-8 EBs were seeded on the scaffold the following day. Media was
changed 2 to 3 times a week until retinal cup formation was visually observed.
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Immunofluorescence Confocal microscopy
from D20 onwards, each week seeded scaffolds were collected to observe for cellular migration
and differentiation using confocal microscopy. Scaffolds were fixed in 4% paraformaldehyde for
5 mins following wash with cold PBS. Scaffold was placed in OCT fluid and cryotome sectioned
and placed on glass slides. Sectioned H9-GCH scaffolds were permeabilized with 0.1 Triton-X for
60 mins. 10% donkey serum containing 0.1% Triton-X solution in PBS was used to block the
samples for 1 hr. Next, the sections were incubated overnight with primary antibodies (listed in
table 2). The slides were washed three times with PBS and blocked again for 1 hr with 10% donkey
serum in order to reduce background fluorescence before incubation with secondary antibodies
conjugated with Cy2, Cy3, or Cy5 (Jackson ImmunoResearch Laboratories, West Grove, PA).
DAPI (4,6-diamidino-2-phenylindole) was used to label the nucleus. Before mounting the slides,
sections were washed three times with PBS and fluorescence images were captured with an LSM
410 spinning-disc confocal microscope and processed using Zen software (Carl Zeiss, Inc,
Thornwood, NY). Images used are representative of 3 or more experiments.

Electron Microscopy
EB seeded scaffolds were fixed in 4% paraformaldehyde. Further fixation was done by immersing
the tissue in 1 % osmium tetroxide for 90 min. Samples were then dehydrated with a graded series
of ethanol (50–100 %) baths, cleared in propylene oxide, and embedded in epoxy resin. Ultrathin
sections were cut with an ultramicrotome and stained with uranyl acetate and lead citrate. Stained
sections were then examined with transmission electron microscopy.
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Quantitative Real-time RT-PCR
Total RNA was extracted using TRIzol reagent (Invitrogen, Paisley) according to manufacturer’s
instructions. cDNA was reverse transcribed using 2µg of total RNA using QuantiTect Reverse
Transcription kit (BioRad). Quantitative reverse transcription polymerase chain reaction qRT-PCR
was synthesized using iTaqSYBR Green (BioRad) and RNA primers generated at Keck
Oligonucleotide synthesis facility (Yale University). Following positive expression, samples were
further tested using customized PCR array for 48 genes specific to early eye field, neural retinal
development, ganglion cells, terminal differentiation of photoreceptors, interneurons and retinal
pigment epithelium lineage. Relative mRNA expression was normalized with housekeeping genes
(GAPDH and Actin) and calculated using 2-∆∆Ct method.

FACS sorting
Differentiating EBs were transfected with the AAV vector carrying the rhodopsin promoter
upstreams of a Tdtomato sequence, which is a red fluorescent protein, 48 hours prior to flow
cytometric cell sorting (FACS). EBs were dissociated with 0.25% trypsin for 15 min and Serum
free media was added to inactivate the trypsin. Cells were spun down at 1000 rpm and strained to
obtain a single cell suspension. Analysis was performed using the FACS Calibur system (BD
Biosciences).

AAV virus preparation
293FT cell line was maintained with DMEM and 10% FBS and passaged 1:4 every 2 days. The
293FT cells were cultured in 150mm dishes. The media is changed when the cells are ready for
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transfection (more than 70% confluent). For every 5x150mm culture dish the vector mix was
prepared with 30 µg AAV vector; AAV rep/cap 50 µg; adenol helper 60 µg. The plasmid is mixed
with 600 µl PEI (1µg/µl) to DNA mixture, vortexed and incubated for 25 min at room temperature.
120µl is added to each plate and cells harvested 48-72 hours post transfection. Collect cells using
centrifugation at 1000g for 10 mins. Cell pellet was resuspended in 6 ml lysis buffer (150 mM
NaCl, 20 mM Tris-HCl pH 8.0). Cells were lysed using subsequent incubation in dry ice/ethanol
mixture and 55 C water bath. 250U/Benzonase was added and incubated at 37C for 1 hour while
vortexing every 15 mins. Cell lysates are centrifuged at 4000 rpm for 30 min and supernatant is
filtered with a 0.45um syringe filter. The HiTrap heparin columns are setup with a 10 ml syringe
and flow is kept below 1ml/mins. The column is equilibrated with 10 ml lysis buffer (150Mm
NaCl, 20Mm Tris-HCl Ph8.0). The viral solution is passed through the column slowly. The column
is washed with 3 ml 200Mm NaCl, 20Mm Tris-HCl Ph8.0, and 3ml 300Mm NaCl, 20Mm TrisHCl Ph8.0 respectively. The virus is eluded with 1.5ml 400Mm NaCl, 20Mm Tris-HCl Ph8.0 and
concentrated with Amico ultra-4 centrifugal filter units, and washed the collection with DPBS.
Finally, aliquoted the concentrated virus and stored in -80C.

Animal experiment
All animal experiments were performed in accordance to the guidelines set and approved by
Institutional animal care and use committee (IACUC) at Yale University, New Haven, CT. A total
of two breeding pairs were required to complete this experiment. This pair was used for breeding
and pups obtained were used for the implantation study. Wild-type and rd10 mice at post-natal day
30 were used for transplantation and following the completion of experiment mice were euthanized
by prolong exposure to CO2 followed by secondary form of euthanasia (lung puncture).
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Wild-type and RD10 mice implantation
For transplantation of GCH scaffold alone or scaffold with differentiated retinal cup tissue, the
scaffold grafts were cut into 0.5 cm dimension and kept in PBS solution. Mice were anesthetized
by intramuscular injection of a mixture of ketamine (100 mg/kg) and xylazine (10 mg/kg). A small
scleral hole was made after conjunctival incision and a local retinal detachment was induced by
PBS injection. Subsequently, the scleral incision was enlarged. The small piece of scaffold was
carefully inserted into the dorsal quadrants of the host retinas. After transplantation, the mice were
transferred into a dark room for 1-2 days, and then maintained in regular animal facility.

Statistical analysis
All data presented in this manuscript is shown as the mean + standard deviation (SD) unless
otherwise indicated. All experiments presented here were completed in biological and technical
triplicates. The data from the experimental sets were compared with controls and statistical
analyses was performed by one-way ANOVA, and p values <0.05 were considered statistically
significant.
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Results
Retinal Progenitor Cell Differentiation on GCH scaffold

*

*

*
*

Figure 5- qRT-PCR was done for monitoring neural retinal maturation on the gelatin scaffold.
Dashed Line: 2X increase vs Day 0. qRT-PCR results are averaged from n=3 separate
experiments. Statistically significant results are marked by asterisk.

The qRT-PCR analysis showed an increase in the expression of neural and early eye field genes
of neurospheres on the GCH scaffold from D10. LHX2 shows a 6-fold increase on D24 compared
to D0. On further testing at D10 and D24, PAX6 expression increased two-fold in comparison to
D10. RAX and LHX2 increased 2-fold (Fig. 5) indicating the EBs on GCH scaffold were
differentiating into RPCs. H9 cultured on GCH shows upregulation of important eye field
transcription factors (RAX, SIX3 and OTX2), photoreceptor genes as evident on Fig. 5.
Immunofluorescence and confocal microscopy of RPCs also shows the upregulation of OTX2,
SOX1 and RAX on D7 as expected. There is also a clear expression of RAX, PROX1, LHX2 at
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D21 which are early eye field genes (Fig. 6). The expression of these markers was comparable to
floating EB cultures which were used as a control.

DAPI

OTX2

MERGE

RX

SOX1

MERGE

RX

MERGE

PROX1

LHX2

MERGE

Day 7
DAPI

Day 21
Figure 6- Confocal microscopic imaging of H9 differentiation in vitro, shows stepwise
expression of early eye field proteins from Day 7 to D21 using immunohistochemistry. Bar
20µm.

Retinal Progenitor Cell interaction with GCH Scaffold
The final GCH fabrication product resulted in a homogenous scaffold with pore sizes ranging from
150-190 µm (Fig. 7 A, B). H9-GCH interaction was confirmed using bright-field and scanning
electron microscope. EBs adhered to the surface of the scaffold (Fig. 7D) and maintained the EB
morphology with a slightly polarized appearance, and some EBs contained the pigmented RPE
which is consistent with differentiation towards a self-organizing neuro-epithelial lineage (Fig
7D). 2 weeks after the EBs were seeded onto the GCH scaffold, DAPI staining was done to assess
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cellular migration within the scaffold. Confocal microscopy revealed that H9 cells attached,
proliferated and migrated through the 60µm-thick scaffold (Fig. 7 E and C).

CC

B
B

A

DD

E

Figure 7- A) Scanning electron microscopy (SEM) image showing macroporous structure
of the scaffold in 3D, B) and 2D view, (scale bars 1.00 mm and 500µm respectively) C)
Human embryonic stem cells (H9) seeded onto gelatin scaffold D20 (scale bar 100µm). D)
ESCs completely infiltrate two weeks after scaffold seeding on BF microscopy. E) ESCs
migrate through the scaffold thickness (3D view) on confocal imaging. Scale bars 20µm.
Images curtesy of Deepti Singh, Yale Univ.
RPC differentiation on GCH scaffold with RPE co-culture
RPCs differentiating on the GCH scaffold were placed on RPE that was cultured on transwell
filters at D20. The differentiation process continued in proximity to the RPE mimicking in vivo
conditions. Samples were taken on D90 and immunofluorescence showed a discrete separation
between recoverin positive cells and LHX2 positive cells as seen in Fig. 8. There was 7-8 rows of
recoverin positive cells adjacent to the RPE layer which is the location of photoreceptor
development in vivo.
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Figure 8- The upper panel Represents confocal imaging of H9 cells on the GCH scaffold
expressing early eye field proteins at D40 (scale bar 20µm). The lower panel demonstrates
ESC differentiation in proximity to RPE cells at D90 (scale bar 50µm). Besides migrating
into the scaffold, cells proliferate as broad flat clusters on the scaffold and recoverin positive
cells (green) segregate from LHX2 positive (red) cells. The recoverin positive cells matured
proximal to the RPE. (Note that the scaffold is autofluorescent and appears in multiple
channels.)

Biocompatibility of RPC/GCH transplantation in wild type mice
To investigate the in-vivo response to RPC-GCH, the scaffold was implanted in the subretinal
space of wild type and RD10 mice. Three weeks post transplantation, the RPC-GCH scaffold
biocompatibility and host inflammatory response was evaluated by IL-6 detection levels in the
tissue. IL-6 staining was found to be minimal at the site of implantation and around the scaffold in
both wild-type and RD10 mice (Fig. 9). In wild-type mice transplanted with RPC-GCH, some IL6 positive staining was found in and around the area of the choroid which is where IL-6 positive
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cells are physiologically present (Fig. 9). However, minimal IL-6 positive cells could be seen at
the site of implant (Fig. 9). There was minimal host inflammatory response to the transplanted
scaffold. Most of the scaffold was degraded 6 weeks post transplantation (figure not shown).

RCV
R

IL-6

DAPI

BF

GCL

GCL

ONL

ONL

RPE
choroid

MERGE

RPE
choroid

choroid

RD10

DAPI

IL-6

MERGE

Scaffold

WILD TYPE
Figure 9- Confocal image of wild type retina 3 weeks post implantation of RPC on GCH
scaffold. IL-6, a major inflammatory marker, was used to demonstrate host response to scaffold.
In both panels there is minimal expression of IL-6 noted suggesting the biocompatible nature
of the fabricated scaffold. IL-6 is seen in the choroid layer in RD10 panel where it is usually
seen in vivo. Scale bar is 20µm.

Migration of transplanted RPC on GCH into host retina
Immunohistochemistry examination of the RPC-GCH implant in the sub-retinal space of wild type
mice 6 weeks after implantation shows minimal inflammation and migration of human antigen
positive cells (TRA-1-85) into other retinal layers of the mice (Fig 10). The TRA-1-85 positive
staining is showing the retinal vascular pattern as the antibody cross reacts with mouse blood cells
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that failed to be removed by saline perfusion post euthanasia. In wild type mice, migration is
minimal unless ONL is diseased or injured. TRA-1-85 positive cells were found within the
transplanted scaffold showing that the RPCs are viable within the GCH scaffold after
transplantation.

DAPI

TRA1-85

TUJ1

TRA1-85

GCL

GCL

RCVR

MERGE

GCL

MERGE

GCL

ONL

Figure 10- RPC/GCH scaffold implants in WT mouse 3 weeks post transplantation. The cells
within the scaffold are positive for human antigen TRA1-85, which shows that mouse cells
did not invade the scaffold in the subretinal space. Some TRA1-85 positive cells show
vasculature pattern in the different layers. RPCs do not migrate when there is not a layer of
injury. Bar, 20µm.
6 weeks post transplantation of GCH/Scaffold in RD10 mice showed the scaffold had been
resorbed. However, RPCs were seen to migrate and adhere to the host retina, adding an extra layer
of cells in the outer nuclear layer (Fig 11). In the ONL there is a layer of TRA1-85 positive cells
adjacent to a row of recoverin positive cells. TRA-1-85 positive cells were seen to extend their
cellular processes and migrate deeper into the ONL layer (Fig. 11) indicating that the implanted
RPC were able to survive transplantation stress, and migrate into the degenerating photoreceptor
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layers. To further confirm cellular migration and attachment of RPC into the ONL layer, samples
were co-stained with recoverin and TRA-1-85 showing a distinct layer of TRA-1-85 positive cells
on top of the homogenous recoverin positive photoreceptors in the ONL (Fig. 11).

GCL
ONL

INL
ONL
RPE
Choroid

ONL
RPE
Choroid

ONL

ONL

ONL
RPE

ONL

RPE

ONL

Figure 11- Confocal images the 6th week post implantation. TRA-1-85 (green), recoverin (red)
and DAPI (blue) cells were found to integrate with the host photoreceptor layer. Recoverin
staining was performed to confirm the retina orientation. The panel shows TRA-1-85 positive
cells at site of implant. The transplanted cells do not express recoverin. At 6 weeks there is
clear attachment of human antigen positive cells at the site of implantation both at the ONL and
RPE layers. Scaffold degraded within the 6th week of implantation allowing migration and
integration of grafted cells into host retina. Figure curtesy of Deepti Singh, Yale Univ.
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FACS Sorting of Rho + transfected RPCs and subretinal injection in RD10 mice
Some cells were lost in the process of developing a single cell suspension for FACS given the
longer exposure to trypsin in order to break up the neurosphere. 20% (2x 10^5 cells) of the RPCs
were expressing rhodopsin, which is expressed in photoreceptors (Fig. 12).

A

B
Figure 12- FACS sorting neurospheres transfected with Td/tomato Rho+ AAV. Photoreceptors
generally differentiate in the periphery which will express rhodopsin at D50. Panel A shows
rhodopsin positive cells in the periphery. Panel B demonstrates a distinct population of Rho+
cells in P4 which will be used to for subretinal injection in RD10 mice.
50,000 cells were injected in one eye of the RD10 mouse. Ku-80 Immunofluorescence, which is
an antibody marking human antigens, shows the presence of a homogenous photoreceptor
population in the subretinal space 3 weeks post injection. The cells were viable and intact through
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the injection process. There was also minimal inflammatory response, given the minimal IL-6 was
observed on immunofluorescence (Fig. 13).
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Figure 13- Subretinal injection of FACS sorted Rho+ cells in the subretinal space of RD10
mouse at P30. Confocal images are 3 weeks post-injection. Ku80 is an antibody against
human antigens. The host cells express recoverin while the injected cells are only Ku-80+.
IL-6 staining shows minimal inflammatory response in the lower panel. The layer labeled
“RPE” includes the underlying choroid.

Discussion
Methods of cellular delivery and survival rate for transplantation has been a technical challenge in
regenerative medicine. The layered and flat retinal anatomy poses a specific challenge for stem
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cell delivery given current stem cell differentiation protocols result in spherical eye cup structures
(26). The gelatin-chondroitin sulfate-hyaluronic acid scaffold approximates the retinal
extracellular composition (27). Gelatin was substituted for collagen, because it is less
immunogenic than the collagen from which it is derived (28). I have shown that the H9 ESCs
differentiate readily on the GCH scaffold compared to the control floating embryoid body cultures.
Early eye field genes such as RAX, LHX2, PAX6, and OTX2 are upregulated as evident by qRTPCR results, immunofluorescence and confocal microscopy. The ESCs migrate through the 60µm
thickness of the scaffold given the interconnected scaffold pore morphology constructed through
rapid freezing and drying using a lyophilizer. Since EB’s are large cell clusters, it is difficult for
most clusters to achieve complete migration in a 3D structure. However, the macroporous
interconnected pores of GCH showed the possibility of attaining 3D cellular growth. The GCH
scaffold was superior in supporting RPC formation and ESC differentiation in comparison to PCL
scaffolds previously studied in the Rizzolo lab. ESCs were mostly aggregated on the surface of the
PCL scaffold given the scaffold did not have the porous structure as the GCH scaffold. Currently,
the members of the Rizzolo lab have found that GCH coating with laminin 521 further enhances
RPC attachment, migration and differentiation.
The RPC/RPE coculture experimental samples clearly formed a planar retinal structure with
recoverin positive cells differentiating adjacent to the RPE layer. These samples were fixed for
immunofluorescence on D90 of the differentiation protocol. These samples were not used for
transplantation studies given the scaffold was partially degraded in culture and did not have the
mechanical stability to be used in animal studies. The scaffold partially degrades when is placed
adjacent to the RPE, possibly due to metalloproteinase secretion by the RPE.
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The scaffold causes minimal host inflammatory response when transplanted in both wild type and
RD10 mice, as there is minimal IL-6 detected on immunofluorescence and there is no retinitis seen
in mice post transplantation. There is no increase in IBA-1 or IL-6 positive cells at the site of
implant or within the vicinity of the scaffold. Few IL-6 positive cells were detected in the
photoreceptor layer in both wild type and RD10 mice at the 1st week post transplantation could be
due to surgical procedure or host response to the graft. However, in the later stages absences of
both types of cells indicates the graft was well tolerated by the host and does not cause a major
inflammatory response.
The GCH scaffold is mostly degraded at 6 weeks post transplantation, however there is a retinal
detachment at the site of transplantation when the scaffold is degraded. The retinal detachment is
caused by the volume of the transplanted scaffold in comparison to the mouse subretinal surface
area. The RPCs are viable within the scaffold when transplanted and there is no invasion of host
cells into the scaffold as evidenced by the presence of TRA1-85, a human antigen marker, seen on
immunofluorescence within scaffold pores.
There is RPC integration within the RD10 outer nuclear layer, which is the site of photoreceptor
loss and injury, 6 weeks post transplantation when the RPC/GCH graft is transplanted. It is thought
that RPCs migrate and home to the site of injury within the retina. This integration is more notable
when the RPCs on the scaffold are transplanted on D20-D24 of differentiation. During that
timeline the cells are in the progenitor state and are more capable of differentiating into different
retinal cells and integrating and further differentiating at the injury site.
FACS analysis of RPCs was done on D50 of the differentiation protocol after transfection with
rhodopsin positive AAV. FACS sorting of 1x106 RPC cells transfected with Rho+ AAV yielded
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only 2x105 Rho+ cells.20% of the RPC population was expressing rhodopsin which is present in
the later stages of photoreceptor differentiation.
The injection of 50,000 Rho+ cells in the subretinal space of RD10 mice resulted in a viable
homogenous photoreceptor cluster in the subretinal space 3 weeks post injection. There was a few
Ku-80+ cells, which is a human antigen marker, seen in the outer nuclear layer. However, it is
unclear if these are the injected human cells which have migrated and integrated in the ONL or the
remaining mouse photoreceptors have taken up the marker through cytoplasmic exchange (29). In
that event, it would appear the transfer of mRNA to host cells had a protective effect. The
transcleral injection of Rho+ cells causes minimal inflammation given there is only one IL-6
positive cell detected at the injection site. The injection does not seem to have disrupted the retina
blood barrier. Integration of rhodopsin expressing photoreceptors into the ONL might be more
difficult, given these cells are almost mature photoreceptors.
Cells in the RPC (differentiation day 20-24) stage can theoretically integrate more readily as
evidenced in Fig. 12 in comparison to more mature RPCs this finding could be explained by the
fact the retinal cups start forming during the D20-D24 timeframe and most of early eye field genes
are expressed within this earlier window. It might be difficult for cells to migrate after complete
commitment to a specific retinal lineage such as in the rhodopsin+ FACS sorted cells
transplantation experiment. For this reason, the Rizzolo lab has acquired a GFP+ SIX6 expressing
ESC line. SIX6 is an early eye field gene, and marks RPCs in an early differentiation stage. The
SIX6+ stem cell population can be cell sorted and used to seed the GCH scaffold for further
transplantation studies or subretinal injection studies.
Retinal functional recovery evaluation post transplantation will be done using multifocal
electroretinogram (mfERG) studies at the site of transplantation. However, in order to achieve any
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measurable functional recovery, it is hypothesized that at least 150,000 RPCs must integrate in the
ONL layer in photoreceptor degenerative diseases (30). The lab is currently working on achieving
a reliable method to perform mfERGs on the mouse models.

Conclusions
The GCH scaffold supported the differentiation and attachment of RPCs. The RPC/RPE co culture
resulted in a polar planar retinal structure with recoverin expressing cells adjacent to the RPE layer.
In this study, we found significant amount of cells migrated into the photoreceptor layers within 6
weeks when RPC-GCH was implanted on differentiation days 20-24. Less integration was seen
when a homogenous photoreceptor population was injected in the subretinal space at a later
differentiation time point. Furthermore, the scaffold was mostly degraded within the 6-week time
frame without altering the retinal architecture or causing any immune rejection. However, there
was a retinal detachment at the site of scaffold transplantation.
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Table 1- qRT-PCR primers

Genes

Forward Sequence 5’-3’

Reverse Sequence 3’5’

Size
(bp)
311

BRN3
CHX10

CTC ACA CTG TCC CAC AAT AAT A
ATT CAA CGA AGC CCA CTA CCC AGA

CCG GCG GAA TAT TTC ATT CT
ATC CTT GGC TGA CTT GAG GAT GGA

229

CRX

TAT TCT GTC AAC GCC TTG GCC CTA

TGC ATT TAG CCC TCC GGT TCT TGA

253

LHX2

CAA GAT CTC GGA CCG CTA CT

CCG TGG TCA GCA TCT TGT TA

284

NANOG

CAA AGG CAA ACA ACC CAC TT

TCT GCT GGA GGC TGA GGT AT

158

NEUROD1

TAC TGC TGC AAA GTG CAA ATA C

AAG TGC TAA GGC AAC ACA ATA AC

539

OCT4

CGA GCA ATT TGC CAA GCT CCT GAA

TTC GGG CAC TGC AGG AAC AAA TTC

324

OTX2

CAA CAG CAG AAT GGA GGT CA

CTG GGT GGA AAG AGA GAA GC TG

429

PAX6

CGG AGT GAA TCA GCT CGG TG

CCG CTT ATA CTG GGC TAT TTT GC

RAX

GAA TCT CGA AAT CTC AGC CC

CTT CAC TAA TTT GCT CAG GAC

300
279

SIX3

CGA GCA GAA GAC GCA TTG CTT CAA

CGG CCT TGG CTA TCA TAC ATC ACA

394

SIX6

ATT TGG GAC GGC GAA CAG AAG ACA

ATC CTG GAT GGG CAA CTC AGA TGT

385

GAPDH

TCACCAGGGCTGCTTTTAAC

GACAAGCTTCCCGTTCTCAG

153

Table 2- Antibody used for immunofluorescence
Antibody
Type
Source
Sox2
Rabbit polyclonal
Abcam
OTX2
Rabbit polyclonal
Novus Biologicals
PAX6
Rabbit polyclonal
Abgent
LHX2
Goat polyclonal
Santa Cruz Biotechnology
CHX10/VSX2
Sheep monoclonal EMD Millipore
RAX
Mouse monoclonal Abnova
Rhodopsin
Rabbit monoclonal Cell Signaling
CRX
Rabbit polyclonal
Novus Biologicals
β-Tubulin-III
Rabbit polyclonal
Abcam
Ki67
Rabbit polyclonal
Thermo Scientifics
CRX
Rabbit monoclonal Novus Biologicals
Recoverin
Rabbit polyclonal
EMD Millipore
TRA-1-85
Mouse monoclonal EMD Millipore
IL-6
Mouse monoclonal Abcam
IBA-1
Goat monoclonal
Abcam

Dilution
IF 1:100
IF 1:100
IF 1:200
IF1:200
IF, 1:200
IF, 1:500
IF, 1:300
IF, 1:200
IF, 1:1500
IF,1:500
IF,1:200
IF, 1:300
IF, 1:200
IF, 1:200
IF, 1:200

